Liraglutide is the original modern GLP-1 receptor agonist and remains a clinically useful option in 2026. It is daily rather than weekly, which makes it different from Wegovy and Mounjaro — and that difference matters for specific patient profiles. Here is what we use it for in our Bangkok clinic.
Liraglutide is a GLP-1 receptor agonist — an injectable peptide that mimics the action of glucagon-like peptide-1, a gut hormone released after meals. It binds to GLP-1 receptors in the pancreas, brain, and stomach, producing the same constellation of effects as other GLP-1 medications: reduced appetite, slowed gastric emptying, and glucose-dependent insulin release.
Structurally, liraglutide is the native human GLP-1 sequence with a 16-carbon fatty acid chain attached. This fatty acid binds to albumin in your bloodstream, protecting the molecule from rapid enzymatic degradation and extending its half-life from about two minutes (native GLP-1) to approximately 13 hours. That's long enough for once-daily injection — but short enough that weekly dosing requires the additional engineering found in semaglutide and tirzepatide.
Liraglutide is sold under two brand names: Saxenda for chronic weight management (maximum dose 3.0 mg daily) and Victoza for Type 2 diabetes (maximum dose 1.8 mg daily). The molecule is identical; the labels and approved maximum doses differ.
The pivotal weight-management trial for liraglutide was SCALE, published in 2015. It enrolled 3,731 non-diabetic adults with BMI ≥30 or ≥27 with comorbidities. Patients on Saxenda 3.0 mg daily lost a mean 8.0% of body weight over 56 weeks, compared to 2.6% in the placebo arm. The net pharmacologic effect — about 5.4% — established liraglutide as a viable pharmacological weight-loss option.
Responder rates: approximately 63% of patients lost at least 5% of body weight, 33% lost at least 10%. These numbers compare favorably to non-pharmacological weight loss but sit clearly below semaglutide (14.9% in STEP-1) and tirzepatide (20.9% in SURMOUNT-1).
Why is liraglutide less potent? Two reasons. First, the dose ceiling — Saxenda maxes at 3.0 mg daily, while semaglutide ramps to 2.4 mg weekly with similar absolute weekly exposure but more consistent receptor occupancy. Second, the engineering — semaglutide's tighter albumin binding produces steadier plasma concentrations than liraglutide's daily peak-and-trough profile. The result is the same receptor target but less continuous activation.
Saxenda titration: 0.6 mg daily for week 1, then increase by 0.6 mg each week until reaching 3.0 mg daily by week 5. Full maintenance dose is 3.0 mg daily, administered subcutaneously. Most patients self-inject in the abdomen or thigh.
Victoza titration: 0.6 mg daily for week 1, then 1.2 mg from week 2, with optional escalation to 1.8 mg for inadequate glycemic response. Lower maximum dose reflects the diabetes label rather than the weight-management label.
The clinical trade-off: daily dosing is more flexible (you can skip a day without major rebound) but requires more discipline to remember. Weekly dosing is more convenient but less forgiving of inconsistency. Patients who travel frequently, who prefer fine-grained dose adjustment, or who have GI sensitivity that benefits from daily smaller doses may prefer liraglutide.
The side-effect profile follows the GLP-1 class pattern: gastrointestinal events dominate, concentrated in the titration phase. In the SCALE trial, nausea was reported by 39% of patients at some point, vomiting by 16%, diarrhea by 21%, constipation by 19%, and abdominal pain by 6%. Most events were mild to moderate.
The discontinuation rate due to adverse events was approximately 9% — somewhat higher than the more modern weekly GLP-1s. This likely reflects the daily peak-and-trough profile producing more episodes of acute GI discomfort versus semaglutide's steadier plasma levels.
Class-level considerations apply: caution with personal or family history of medullary thyroid carcinoma or MEN-2 syndrome, monitoring for pancreatitis, and standard guidance about cessation if persistent severe abdominal pain develops. Cardiovascular safety has been demonstrated in the LEADER trial — liraglutide reduces major adverse cardiac events in high-risk Type 2 diabetes populations.
In our Bangkok clinic, liraglutide remains useful for specific patient profiles even though weekly GLP-1s now dominate. The clinical situations where we consider liraglutide first include the following.
Patients who prefer daily dosing — some people find a daily routine easier to maintain than a weekly schedule. The discipline of injection at the same time each day becomes part of the routine rather than a separate event to remember.
Patients with GI sensitivity who have failed weekly dosing — smaller daily exposures can be more tolerable than larger weekly peaks for some patients.
Patients with diabetes prioritizing the longest cardiovascular safety record — Victoza's LEADER trial provides mature cardiovascular outcome data.
Patients who have stopped weekly GLP-1 and need a step-down option — daily liraglutide can serve as a bridging therapy during structured discontinuation.
For most weight-loss-focused patients in 2026, however, our default starting point is Wegovy or Mounjaro rather than Liraglutide. The potency gap is too large to ignore when the goal is meaningful weight loss.
If you're considering Liraglutide and want to compare options, the relevant alternatives in 2026 are clear.
For weight loss with a weekly dosing schedule, Wegovy (semaglutide 2.4 mg weekly) typically delivers approximately 14.9% mean weight loss — roughly double liraglutide's 6-8%. For maximum weight loss, Mounjaro (tirzepatide) typically delivers approximately 20.9%.
For diabetes-focused therapy with the longest track record, Victoza (liraglutide 1.8 mg daily) remains appropriate — but for most newly-diagnosed patients in 2026, semaglutide-based Ozempic or tirzepatide-based Mounjaro offer stronger glycemic and weight outcomes.
We cover the broader class picture in GLP-1 Medications Explained, and the cross-comparison details in Mounjaro vs Wegovy.
"Liraglutide is the elder of the family. Less potent than the newer molecules, but more proven. We use it when the patient and the molecule are the right match — not as a default starting point."
Authentic Liraglutide — Saxenda for weight management, Victoza for diabetes — is available in Thailand through licensed pharmacies with cold-chain delivery. The molecule must be refrigerated; once in use, it's stable at room temperature for up to 30 days. Pricing in Thailand is competitive with regional Asia-Pacific markets and meaningfully below US cash-pay rates. Doctor-led titration ensures the daily dose schedule is followed correctly.
Yes. Saxenda is the brand name for liraglutide 3.0 mg daily used for chronic weight management. Victoza is the brand name for liraglutide 1.8 mg max used for Type 2 diabetes. Same molecule, different doses and labels.
Average about 6-8% of body weight at the Saxenda 3.0 mg dose over 56 weeks in the SCALE trial. Less than semaglutide (14.9%) or tirzepatide (20.9%). Individual results depend on starting BMI, dose tolerance, and adherence.
Liraglutide has a 13-hour plasma half-life. Modern weekly GLP-1s like semaglutide have 7-day half-lives thanks to additional engineering. The shorter half-life of liraglutide requires daily dosing to maintain receptor occupancy.
It depends on your routine. Daily dosing builds into your morning or evening routine and becomes automatic. Weekly dosing is fewer total injections but requires remembering one specific day. Patient preference varies.
All three have well-characterized safety profiles. Liraglutide has the longest cumulative human exposure (since 2010), but semaglutide and tirzepatide have added their own substantial safety data. No clear safety advantage to liraglutide in 2026.
Yes. Most patients restart at the lowest dose of the new molecule (Wegovy 0.25 mg or Mounjaro 2.5 mg) and titrate up. There is no fixed washout period required for the switch.
Yes. Authentic Saxenda (Novo Nordisk) and Victoza (Novo Nordisk) are available through licensed Thai pharmacies with cold-chain delivery. Doctor-led titration is required.
Rarely in non-diabetic patients. The GLP-1 mechanism is glucose-dependent — insulin release is triggered only when blood sugar is elevated. Patients with diabetes already on insulin or sulfonylureas need dose review.
Refrigerated at 2-8°C until first use. Once in use, the pen can be kept at room temperature (below 30°C) for up to 30 days. Avoid direct sunlight and never freeze.
Take the missed dose as soon as you remember on the same day. Skip it entirely if more than 12 hours have passed and continue with the next scheduled dose. Do not double-dose.
A 30-minute consultation evaluates whether daily liraglutide fits your goals — or whether a weekly option would serve you better.
Request consultation' + eyebrows[toolKey] + '
' + '' + taglines[toolKey] + '
' + '' + WA_ICON + '' + initialText + ' →' + '' + /* v33: microcopy removed — green CTA is self-evidently WhatsApp + status below has all the context */ 'Consultation · ' + replyTimingShort() + ' · no spam
' + ''; /* Live-update CTA when tool state changes (best-effort via polling) */ var ctaA = wrap.querySelector('[data-track-one]'); var ctaLabel = wrap.querySelector('[data-cta-label]'); var lastCtxStr = JSON.stringify(initialCtx); setInterval(function() { var ctx = readToolContext(toolKey); var cs = JSON.stringify(ctx); if (cs === lastCtxStr) return; lastCtxStr = cs; var newText = buildCTAText(toolKey, ctx); var newMsg = buildPrefilledMessage(toolKey, ctx, pageTopic); ctaA.href = 'https://wa.me/' + WA_NUMBER + '?text=' + encodeURIComponent(newMsg); ctaLabel.textContent = newText + ' →'; }, 1500); /* Track-1 click event */ ctaA.addEventListener('click', function() { if (typeof gtag === 'function') { gtag('event', 'wl_v2_track1_click', { tool: toolKey, page: location.pathname }); } }); /* Track-2 submit */ var form = wrap.querySelector('form'); form.addEventListener('submit', function(e) { e.preventDefault(); var btn = form.querySelector('button'); var status = wrap.querySelector('.trt-wl-v2-status'); var cc = form.cc.value; var phoneRaw = (form.phone.value || '').replace(/[^0-9]/g, ''); if (phoneRaw.length < 6) { status.textContent = 'Please enter a valid phone number.'; status.style.color = '#FCD34D'; return; } var fullPhone = cc + ' ' + phoneRaw; btn.disabled = true; btn.textContent = 'Sending…'; status.style.color = '#FFFFFF'; status.textContent = ''; var ctx = readToolContext(toolKey); var payload = { location: 'wl-v2-' + toolKey, name: '', email: '', whatsapp: fullPhone, phone: fullPhone, country_code: cc, current_weight: ctx.current_weight || '', goal_weight: ctx.goal_weight || '', preferred_drug: ctx.drug || ctx.match || '', tool: toolKey, tool_context: JSON.stringify(ctx), page: location.pathname.replace(/^\//, '').replace(/\/$/, ''), page_type: document.body.dataset.pageType || 'wl-spoke', page_topic: pageTopic, referrer: document.referrer || '', source_url: location.href }; var fetchPromise = ENDPOINT ? fetch(ENDPOINT, { method: 'POST', mode: 'no-cors', headers: { 'Content-Type': 'text/plain;charset=utf-8' }, body: JSON.stringify(payload) }).then(function() { return true; }).catch(function() { return false; }) : Promise.resolve(false); fetchPromise.then(function(ok) { if (typeof gtag === 'function') { gtag('event', 'wl_v2_track2_submit', { tool: toolKey, page: location.pathname, ok: ok }); } status.style.color = '#0F6E56'; status.textContent = isClinicOpenNow() ? '✓ Thanks! We\'ll WhatsApp you within minutes. Opening WhatsApp now…' : '✓ Thanks! We\'ll WhatsApp you within 2 hours. Opening WhatsApp now…'; btn.textContent = '✓ Sent'; /* Also open WhatsApp for the user — high-intent flow */ var msg = buildPrefilledMessage(toolKey, ctx, pageTopic) + ' My number: ' + fullPhone + '.'; var waUrl = 'https://wa.me/' + WA_NUMBER + '?text=' + encodeURIComponent(msg); setTimeout(function() { window.open(waUrl, '_blank'); }, 600); }); }); return wrap; } /* ============================================================ * 3) Read live tool state — best-effort DOM scraping per tool * ============================================================ */ function readToolContext(toolKey) { if (toolKey === 'wow-stat') { var sec = document.getElementById('wow-stat'); if (!sec) return {}; var nums = sec.querySelectorAll('input[type="number"], input[type="text"]'); var cur = nums.length ? parseFloat(nums[0].value) : null; /* Look for goal weight in displayed text like "you'd weigh 67.2 kg" */ var txt = sec.textContent || ''; var m = txt.match(/(\d+(?:\.\d+)?)\s*kg/g); var goal = null; if (m && m.length) { var nums2 = m.map(function(s) { return parseFloat(s); }); /* The smaller number in the section after "weigh" is likely the goal */ var weighIdx = txt.search(/weigh\s*$/i); var idx = txt.search(/weigh\s+/i); if (idx > -1) { var after = txt.slice(idx + 5); var gm = after.match(/(\d+(?:\.\d+)?)\s*kg/); if (gm) goal = parseFloat(gm[1]); } } return { current_weight: cur && !isNaN(cur) ? cur : null, goal_weight: goal, drug: 'Mounjaro' /* WOW-Stat on hub is Mounjaro-focused */ }; } if (toolKey === 'estimator') { var sec2 = document.getElementById('estimator'); if (!sec2) return {}; /* Find selected drug tab (visually highlighted button) */ var drug = null; var btns = sec2.querySelectorAll('button, [role="tab"], div[data-drug]'); for (var i = 0; i < btns.length; i++) { var b = btns[i]; var bg = window.getComputedStyle(b).backgroundColor; var txt2 = (b.textContent || '').trim(); if (/^(Mounjaro|Wegovy|Retatrutide|Tirzepatide|Ozempic|Semaglutide|Saxenda|Zepbound)$/i.test(txt2.split('\n')[0])) { if (bg && bg !== 'rgba(0, 0, 0, 0)' && bg !== 'transparent') { /* heuristic: dark blue = selected */ if (/24, 95, 165|29, 51, 91|0, 100|29,51,91/.test(bg.replace(/\s/g, ''))) { drug = txt2.split('\n')[0].trim(); break; } } if (!drug) drug = txt2.split('\n')[0].trim(); } } var inputs = sec2.querySelectorAll('input[type="number"], input[type="text"]'); var cw = inputs.length > 0 ? parseFloat(inputs[0].value) : null; var gw = inputs.length > 1 ? parseFloat(inputs[1].value) : null; return { drug: drug || 'Mounjaro', current_weight: cw && !isNaN(cw) ? cw : null, goal_weight: gw && !isNaN(gw) ? gw : null }; } if (toolKey === 'quiz') { var sec3 = document.getElementById('quiz'); if (!sec3) return {}; var matchTxt = sec3.textContent.match(/Your\s+(?:match|recommendation)[\s:]+([A-Za-z][A-Za-z\s\-]+?)(?:\.|$|\n)/i); return { match: matchTxt ? matchTxt[1].trim() : null }; } return {}; } /* ============================================================ * v30: Hub-Quiz → Teaser-CTA (replaces inline quiz on hub-page) * Inside section#quiz: hide quiz form/steps, inject single CTA * that links to /weight-loss-calculator/ * ============================================================ */ function injectQuizTeaser() { var sec = document.getElementById('quiz'); if (!sec) return false; if (sec.querySelector('.trt-quiz-teaser-cta')) return true; /* already injected */ /* Hide quiz form content but keep heading + sub */ var hideStyle = document.createElement('style'); hideStyle.id = 'trt-hub-quiz-hide'; hideStyle.textContent = [ /* hide all step content + back/next buttons inside #quiz, keep only the heading area */ '#quiz [class*="step-"], #quiz .step, #quiz [class*="quiz-step"]{display:none!important;}', /* hide any input/select/button/form inside #quiz */ '#quiz form, #quiz input, #quiz select, #quiz button:not(.trt-quiz-teaser-cta), #quiz .nav-row, #quiz .progress-bar{display:none!important;}', /* hide nested div containers that hold the quiz form (heuristic: divs with multiple inputs as descendants) */ '#quiz > div > div:has(input), #quiz > div > div:has(select){display:none!important;}' ].join('\n'); document.head.appendChild(hideStyle); /* Build the CTA */ var ctaWrap = document.createElement('div'); ctaWrap.className = 'trt-quiz-teaser-wrap'; ctaWrap.style.cssText = 'max-width:560px;margin:24px auto 0;padding:0 20px;text-align:center;'; ctaWrap.innerHTML = '' + 'Start Your 2-Minute Assessment →' + 'Reviewed by Dr. Kenika Norrachetdecha, MD · Thai License #72509
'; /* Append directly to the section (most robust against React re-render) */ sec.appendChild(ctaWrap); /* Hover handler */ var cta = ctaWrap.querySelector('a'); cta.addEventListener('mouseenter', function() { cta.style.background = '#2A4A7F'; }); cta.addEventListener('mouseleave', function() { cta.style.background = '#1D335B'; }); cta.addEventListener('click', function() { if (typeof gtag === 'function') gtag('event', 'wl_hub_quiz_teaser_click', { destination: '/weight-loss-calculator/' }); }); return true; } /* ============================================================ * 4) Inject modules as siblings AFTER each tool section * v39: Back to sibling-inject (React-safe), but with section-background-bridge * via injected CSS that extends the tool-section visual into the v2-modul. * ============================================================ */ /* ============================================================ * v49: Runtime width-sync — kein CSS-calc-Glücksspiel mehr. * Measure inner card's actual bounding rect → apply identical * width + left-offset to v2 module via inline-style. * Adapts to ANY viewport (320px → 4K), survives React re-renders, * and survives Site-CSS conflicts since inline-style wins. * ============================================================ */ function syncCardWidths() { var pairs = [ { sectionId: 'wow-stat', innerSel: ':scope > div' }, { sectionId: 'estimator', innerSel: ':scope > div > div.bg-white' } ]; var wowInnerRect = null; /* v50: capture wow-stat inner for trust-bar sync */ pairs.forEach(function(p) { var sec = document.getElementById(p.sectionId); if (!sec) return; var inner = sec.querySelector(p.innerSel); var v2 = document.querySelector('.trt-wl-v2[data-tool="' + p.sectionId + '"]'); if (!inner || !v2) return; var innerRect = inner.getBoundingClientRect(); if (p.sectionId === 'wow-stat') wowInnerRect = innerRect; /* offsetLeft of inner relative to v2's parent (= section's parent = body usually) */ var v2ParentRect = v2.parentNode.getBoundingClientRect(); var leftOffset = innerRect.left - v2ParentRect.left; var width = innerRect.width; /* Apply via inline-style — beats all CSS-cascade */ v2.style.setProperty('width', width + 'px', 'important'); v2.style.setProperty('max-width', width + 'px', 'important'); v2.style.setProperty('margin-left', leftOffset + 'px', 'important'); v2.style.setProperty('margin-right', '0', 'important'); /* Also sync background of section to body bg, kill any divider borders */ sec.style.setProperty('background', 'rgb(240, 245, 250)', 'important'); sec.style.setProperty('border-top', '0', 'important'); sec.style.setProperty('border-bottom', '0', 'important'); }); /* v50: sync .page-trust-bar width + leftOffset to match wow-stat inner card (third shell of ONE-CARD) */ if (wowInnerRect) { var trustBar = document.querySelector('.page-trust-bar'); if (trustBar) { var tbParentRect = trustBar.parentNode.getBoundingClientRect(); var tbLeftOffset = wowInnerRect.left - tbParentRect.left; trustBar.style.setProperty('width', wowInnerRect.width + 'px', 'important'); trustBar.style.setProperty('max-width', wowInnerRect.width + 'px', 'important'); trustBar.style.setProperty('margin-left', tbLeftOffset + 'px', 'important'); trustBar.style.setProperty('margin-right', '0', 'important'); } /* v50: also kill page-trust-bar-wrap inline border-top/bottom + sync bg */ var tbWrap = document.querySelector('section.page-trust-bar-wrap'); if (tbWrap) { tbWrap.style.setProperty('background', 'rgb(240, 245, 250)', 'important'); tbWrap.style.setProperty('border-top', '0', 'important'); tbWrap.style.setProperty('border-bottom', '0', 'important'); tbWrap.style.setProperty('padding-top', '0', 'important'); tbWrap.style.setProperty('padding-bottom', '0', 'important'); tbWrap.style.setProperty('margin-top', '0', 'important'); } } } /* ============================================================ * v53 · HERO DE-CLUTTER (SICHERE Version — exakte DOM-Targets statt blindes text-content match) * Hide redundant trust signals + distractors that duplicate the page-trust-bar 2000px below. * v52 ROLLBACK: text-content match war zu breit, hat Parent-Hero erwischt. * v53 Fix: spezifische class-Anforderungen + children-count guards + text-length guards. * ============================================================ */ function hideHeroNoise() { /* T1: Bullet trust list parent — div.flex.flex-col mit EXAKT 3 children wobei first child mit "Authentic Mounjaro" beginnt. KANN unmöglich Hero-Parent treffen. */ document.querySelectorAll('div.flex.flex-col').forEach(function(div) { if (div.__trtHidden) return; if (div.children.length !== 3) return; var firstChildText = (div.children[0].innerText || '').trim(); if (firstChildText.indexOf('Authentic Mounjaro') === 0) { div.style.setProperty('display', 'none', 'important'); div.__trtHidden = true; } }); /* v54: T2 (Doctor block) RAUS — Dr. Kenika mit rundem Foto ist wichtiger Authority/Humanization-Trust-Signal, bleibt sichtbar. */ /* T3: Mon-Sat status — p.font-body mit "Mon" + ("AM"|"Sat") — sehr spezifisch, kein anderes p hat genau diese kombo. */ document.querySelectorAll('p.font-body').forEach(function(p) { if (p.__trtHidden) return; var t = p.innerText || ''; if (t.indexOf('Mon') >= 0 && (t.indexOf('AM') >= 0 || t.indexOf('Sat') >= 0)) { p.style.setProperty('display', 'none', 'important'); p.__trtHidden = true; } }); } function inject() { injectHideCSS(); /* v52: hero de-clutter (run early so user sees clean hero ASAP) */ hideHeroNoise(); /* Quiz: replace with teaser CTA to /weight-loss-calculator/ */ injectQuizTeaser(); /* Tools: inject AFTER wow-stat + estimator as siblings */ var tools = ['wow-stat', 'estimator']; tools.forEach(function(key) { var sec = document.getElementById(key); if (!sec) return; /* v46: kill whitespace-only text nodes inside section that create the 3px trailing gap */ Array.prototype.slice.call(sec.childNodes).forEach(function(n) { if (n.nodeType === 3 && !(n.textContent && n.textContent.trim())) { n.parentNode.removeChild(n); } }); /* v47/v48/v49: inline-style overrides — beats site's higher-specificity rules. */ sec.style.setProperty('background', 'rgb(240, 245, 250)', 'important'); sec.style.setProperty('border-top', '0', 'important'); sec.style.setProperty('border-bottom', '0', 'important'); /* Skip if module already a sibling */ if (sec.nextElementSibling && sec.nextElementSibling.classList && sec.nextElementSibling.classList.contains('trt-wl-v2') && sec.nextElementSibling.getAttribute('data-tool') === key) return; var mod = buildModule(key); if (sec.parentNode) { sec.parentNode.insertBefore(mod, sec.nextSibling); } }); /* Remove any existing v2-module that was previously injected under #quiz */ var oldQuizMod = document.querySelector('.trt-wl-v2[data-tool="quiz"]'); if (oldQuizMod) oldQuizMod.remove(); /* v49: width-sync after inject — schedule multiple times to catch late layout shifts */ syncCardWidths(); [50, 200, 600, 1500, 3000].forEach(function(ms) { setTimeout(syncCardWidths, ms); setTimeout(hideHeroNoise, ms); /* v52: re-apply hide after potential React re-render */ }); /* v60: sticky-CTA visibility manager — hide bottom sticky when any baby-blue in-page CTA visible */ setTimeout(initStickyCtaObserver, 1000); /* v63: JS-driven press feedback (CSS :active was beaten by v51 cascade-war) */ setTimeout(initPressFeedback, 800); /* v66: fix Tailwind bracket-class SVG widths (w-[22px] etc. render as 0 width) */ fixBrokenSvgIcons(); [100, 500, 1500, 3000].forEach(function(ms) { setTimeout(fixBrokenSvgIcons, ms); }); } /* ============================================================ * v66 · Fix broken Tailwind bracket-class SVG widths * SVGs with class="w-[22px] h-[22px]" sometimes render at 0×0 * (Tailwind brackets not always parsed by the runtime CSS). * Solution: parse the class, set width/height attributes directly * on the SVG element — HTML attributes beat CSS for SVG sizing. * ============================================================ */ function fixBrokenSvgIcons() { var svgs = document.querySelectorAll('svg[class*="w-["], svg[class*="h-["]'); svgs.forEach(function(svg) { if (svg.__trtSvgFixed) return; var cls = svg.getAttribute('class') || ''; var wm = cls.match(/w-\[(\d+)px\]/); var hm = cls.match(/h-\[(\d+)px\]/); if (wm) svg.setAttribute('width', wm[1]); if (hm) svg.setAttribute('height', hm[1]); if (wm || hm) { svg.style.setProperty('width', (wm ? wm[1] : (hm ? hm[1] : '24')) + 'px', 'important'); svg.style.setProperty('height', (hm ? hm[1] : (wm ? wm[1] : '24')) + 'px', 'important'); svg.style.setProperty('flex-shrink', '0', 'important'); svg.__trtSvgFixed = true; } }); } /* ============================================================ * v65 · JS-driven Press Feedback (PRONOUNCED scale + 150ms hold) * pointerdown → scale(0.85) + dark bg overlay via inline !important * pointerup → animate back (snappy 0.18s ease-out) * Uses element.animate() Web Animations API as backup if transition fails. * ============================================================ */ function initPressFeedback() { if (window.__trt_press_init) return; window.__trt_press_init = true; var SELECTORS = [ '.trt-quiz-teaser-cta', '.trt-hero-cta', 'a.wa-cta', '.trt-wl-v2-cta', 'a[class*="border-white"][class*="rounded-"]', 'a[class*="bg-[#8DBFE2]"][class*="rounded-"]', ].join(','); var pressed = null; var minHoldTime = 150; /* ms — minimum visual press time so user sees it */ function addPress(e) { var t = e.target.closest(SELECTORS); if (!t) return; if (pressed && pressed.el === t) return; pressed = { el: t, startTime: performance.now() }; /* Disable existing transition first so the scale change is INSTANT */ t.style.setProperty('transition', 'none', 'important'); t.style.setProperty('transform', 'scale(0.85)', 'important'); t.style.setProperty('opacity', '0.80', 'important'); t.style.setProperty('filter', 'brightness(0.85)', 'important'); /* Force reflow to commit the no-transition + scale state */ void t.offsetHeight; } function releaseNow(p) { /* now turn transition back on for SMOOTH return */ p.el.style.setProperty('transition', 'transform 0.22s cubic-bezier(.34,1.56,.64,1), opacity 0.22s ease, filter 0.22s ease', 'important'); p.el.style.removeProperty('transform'); p.el.style.removeProperty('opacity'); p.el.style.removeProperty('filter'); /* cleanup transition override after return animation completes */ setTimeout(function() { p.el.style.removeProperty('transition'); }, 240); } function removePress() { if (!pressed) return; var p = pressed; pressed = null; /* Ensure minimum hold time so user perceives press visually */ var elapsed = performance.now() - p.startTime; var wait = Math.max(0, minHoldTime - elapsed); setTimeout(function() { releaseNow(p); }, wait); } document.addEventListener('pointerdown', addPress, { passive: true }); document.addEventListener('pointerup', removePress, { passive: true }); document.addEventListener('pointercancel', removePress, { passive: true }); document.addEventListener('touchend', removePress, { passive: true }); document.addEventListener('touchcancel', removePress, { passive: true }); document.addEventListener('mouseup', removePress, { passive: true }); } /* ============================================================ * v60 · Sticky-CTA Visibility Manager * CRO best-practice (Hims/Apple): hide the bottom sticky-cta * when an in-page primary CTA (baby-blue) is visible — no * decision-paralysis from two competing CTAs on screen. * ============================================================ */ function initStickyCtaObserver() { if (window.__trt_sticky_obs) return; /* idempotent */ var sticky = document.querySelector('.sticky-cta'); if (!sticky) return; /* Watch all v2-modules (each has a baby-blue CTA inside) */ var watch = Array.prototype.slice.call(document.querySelectorAll('.trt-wl-v2')); if (!watch.length) return; var visibleSet = new Set(); function updateSticky() { if (visibleSet.size > 0) { sticky.style.setProperty('opacity', '0', 'important'); sticky.style.setProperty('pointer-events', 'none', 'important'); sticky.style.setProperty('transform', 'translateY(100%)', 'important'); } else { sticky.style.removeProperty('opacity'); sticky.style.removeProperty('pointer-events'); sticky.style.removeProperty('transform'); } } var obs = new IntersectionObserver(function(entries) { entries.forEach(function(e) { if (e.isIntersecting && e.intersectionRatio > 0.4) { visibleSet.add(e.target); } else { visibleSet.delete(e.target); } }); updateSticky(); }, { threshold: [0, 0.4, 1] }); watch.forEach(function(el) { obs.observe(el); }); window.__trt_sticky_obs = obs; } /* v49: Re-sync on viewport changes (orientation, resize) and on React re-renders */ window.addEventListener('resize', function() { /* debounce */ clearTimeout(window.__trt_wl_v2_resize_t); window.__trt_wl_v2_resize_t = setTimeout(syncCardWidths, 100); }); window.addEventListener('orientationchange', function() { setTimeout(syncCardWidths, 200); }); /* Observe DOM mutations on wow-stat and estimator sections to catch React re-renders */ if (typeof MutationObserver !== 'undefined') { var mo = new MutationObserver(function() { clearTimeout(window.__trt_wl_v2_mo_t); window.__trt_wl_v2_mo_t = setTimeout(syncCardWidths, 50); }); setTimeout(function() { ['wow-stat', 'estimator'].forEach(function(id) { var el = document.getElementById(id); if (el) mo.observe(el, { childList: true, subtree: true, attributes: true, attributeFilter: ['style', 'class'] }); }); }, 1500); } if (document.readyState === 'loading') { document.addEventListener('DOMContentLoaded', inject); } else { inject(); } /* Re-run after React-hydration in case tools render late */ setTimeout(inject, 800); setTimeout(inject, 2000); })();